The use of antifungal creams and combinations of antifungal treatments with corticosteroids has been identified as a significant factor contributing to the rise and spread of severe skin, scalp, and nail fungal infections. Recently, dermatologists in the United States detected the first cases of highly contagious drug-resistant fungal skin infections that do not respond to existing antifungal treatments. Initially concentrated in Southeast Asia, these drug-resistant infections have now spread to China and beyond, with reports of cases in at least 11 states in the US. This alarming trend has prompted researchers at the US Centers for Disease Control and Prevention (CDC) to investigate the prescribing practices of antifungal medications in order to gain crucial insights and address the issue before it worsens.
To understand the current landscape of antifungal prescriptions, the CDC researchers thoroughly examined a year’s worth of data on antifungal prescriptions in the US. The study involved analyzing approximately 1 million health professionals who prescribed medications for nearly 49 million Medicare-covered individuals in 2021. The findings revealed that approximately 6.5 million topical antifungal prescriptions were filled during that year, amounting to a staggering cost of $231 million. However, it is important to note that the actual volume of topical antifungal usage is likely higher due to the availability of over-the-counter options without a prescription.
Among the healthcare professionals prescribing antifungal medications, primary care physicians accounted for 40 percent of the total prescriptions, followed by nurse practitioners, dermatologists, and podiatrists. Interestingly, the top 10 percent of antifungal prescribers, amounting to 13,106 practitioners, filled almost half of the total medications. This raises concerns about the potential overuse or liberal prescribing, as these practitioners may either encounter a higher number of patients with suspected fungal infections or be excessively inclined to treat them. However, due to the Medicare data’s limitations, the researchers were unable to determine if patients received the appropriate medication for their specific conditions or if diagnostic testing was performed before prescribing.
Of particular concern to the researchers was the significant number of clotrimazole-betamethasone prescriptions, which accounted for 15 percent of all topical antifungals prescribed. This combination treatment has been identified as a potential driver of emerging drug-resistant tinea, also known as dermatophytosis. The reliance on this particular medication raises red flags as it may contribute to the spread of drug-resistant fungal infections.
Another area of concern highlighted by the researchers is the common practice among healthcare providers, including board-certified dermatologists, of diagnosing skin conditions solely through visual observation. This approach often leads to incorrect diagnoses. To curb the emergence and spread of antimicrobial-resistant fungal infections and promote the appropriate use of topical antifungal medications, the researchers emphasize the importance of diagnostic testing whenever possible. Confirming suspected superficial fungal infections through proper testing would enable healthcare providers to prescribe the most effective medication for each individual case.
As the use of antifungal creams and combination treatments with corticosteroids continues to rise, it is crucial to address the associated risks. The CDC’s study reveals the alarming spread of severe drug-resistant fungal infections and the need for improved prescribing practices. By promoting judicious prescribing, encouraging diagnostic testing, and educating patients about the appropriate use of antifungal medications, healthcare providers can play a pivotal role in controlling the emergence and spread of drug-resistant fungal infections. It is imperative to act swiftly to prevent the situation from worsening and protect public health.
Leave a Reply